An observational study in Fabry Disease, sponsored by Ulla Feldt-Rasmussen. Completed at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2018-10-16.
Sponsored by Ulla Feldt-Rasmussen · Observational
The aim of this study was to investigate renal function decline by measured glomerular filtration rate (mGFR) in patients with FD during enzyme replacement therapy, and to explore the influence of age on renal function in FD.
Nephropathy is common in Fabry disease (FD). Renal function decline is often the first sign of major organ involvement, sometimes progressing to end-stage renal failure. Available studies of renal function during enzyme replacement therapy have shown inconsistent results, and are based on different composition of patient materials and follow-up time.
Most investigations have used estimated glomerular filtration rate (eGFR) for evaluating renal function. GFR is an important indicator of renal function. eGFR based on a serum creatinine measurement is most commonly used in FD. However, this method has been shown to be unreliable, as serum creatinine levels are influenced by other factors than renal function such as ethnic group, muscle mass, age, hydration and diet. Performance of eGFR in detecting minor changes in renal function is poor. A 10 year old review on renal function evaluation in patients with FD recommended the use of GFR based on an exogenous marker, e.g. Cr-EDTA. Nevertheless, only few studies have used mGFR for evaluation of renal function and to our knowledge, the present study is the first to describe the rate of renal function decline with consecutive mGFR values in a nationwide population of patients with FD.
Renal function declines with age in renal healthy individuals. To our knowledge, the present study is the first to age-standardize renal function in patients with FD to adjust for age-dependent renal deterioration.
242 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
This study's enrollment of 52 is below the median of 100 across 123 observational studies indexed under Fabry Disease.
Browse Fabry Disease studies →Ulla Feldt-Rasmussen is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Fabry disease
Exclusion Criteria:
All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
Also known as: Fabrazyme (agalsidase beta), Replagal (agalsidase alfa)
measured glomerular filtration rate
GFR was measured at least once a year by the one sample 51Cr-ethylenendiaminetetra acetic acid (EDTA) clearance technique using two (for duplicate determination) plasma samples 200 min after the injection of 4 (3.8-4.2) MBq 51Cr-EDTA. In children (\< 15y) the injected 51Cr-activity was 3 MBq, and the blood-samples were collected 120 min after radiotracer injection. (\< 5y: 2 MBq).
Time frame: Assessed every 6-12 months; from baseline and up to 15 years
urinary protein excretion
Repeated twenty-four hour urine samples were collected by patients at home, the last 24 hours before coming to the hospital. These samples were analysed for albumin, creatinine and protein. Furthermore spot urine samples were applied and analysed for albumin, creatinine and protein. Albumin-creatinine-ratio was calculated and abnormal values were defined as \> 30 mg/g. Urine protein- and albumin values below detection limit (\< 0.04 g/L and \< 3 mg/L, respectively) were converted to zero for statistical analyses.
Time frame: Assessed every 6-12 months; from baseline and up to 15 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ulla Feldt-Rasmussen